{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:31:07Z","timestamp":1790317867335,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre for Pharmaceutical Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11095-019-2684-6","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T01:04:02Z","timestamp":1579655042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity"],"prefix":"10.1007","volume":"37","author":[{"given":"Loujin","family":"Houdaihed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"issue":"2","key":"2684_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3747\/co.19.1024","volume":"19","author":"JPM Ayoub","year":"2012","unstructured":"Ayoub JPM, Verma S. Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol. 2012;19(2):91\u2013105.","journal-title":"Curr Oncol"},{"issue":"8","key":"2684_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/bjc.2012.85","volume":"106","author":"A Gallardo","year":"2012","unstructured":"Gallardo A, Lerma E, Escuin D, Tibau A, Mu\u00f1oz J, Ojeda B, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 2012;106(8):1367\u201373.","journal-title":"Br J Cancer"},{"issue":"6","key":"2684_CR3","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","volume":"23","author":"MP DiGiovanna","year":"2005","unstructured":"DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol. 2005;23(6):1152\u201360.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2684_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","volume":"4","author":"RE Kontermann","year":"2012","unstructured":"Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012;4(2):182\u201397.","journal-title":"MAbs."},{"issue":"5","key":"2684_CR5","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/jps.23934","volume":"103","author":"Y Liu","year":"2014","unstructured":"Liu Y, Sun J, Lian H, Cao W, Wang Y, He Z. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci. 2014;103(5):1538\u201347.","journal-title":"J Pharm Sci"},{"issue":"1","key":"2684_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/cddis","volume":"3","author":"GMA Ajabnoor","year":"2012","unstructured":"Ajabnoor GMA, Crook T, Coley HM. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis. 2012;3(1):e260. https:\/\/doi.org\/10.1038\/cddis.","journal-title":"Cell Death Dis"},{"issue":"7","key":"2684_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ctrv.2012.02.011","volume":"38","author":"S Murray","year":"2012","unstructured":"Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 2012;38(7):890\u2013903.","journal-title":"Cancer Treat Rev"},{"key":"2684_CR8","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590\u20138.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2684_CR9","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1021\/acs.molpharmaceut.8b00217","volume":"15","author":"L Houdaihed","year":"2018","unstructured":"Houdaihed L, Evans JC, Allen C. Codelivery of paclitaxel and Everolimus at the optimal synergistic ratio: a promising solution for the treatment of breast cancer. Mol Pharm. 2018;15(9):3672\u201381.","journal-title":"Mol Pharm"},{"issue":"4","key":"2684_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","volume":"54","author":"AP Chapman","year":"2002","unstructured":"Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54(4):531\u201345.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2684_CR11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1021\/mp400315p","volume":"10","author":"B Hoang","year":"2013","unstructured":"Hoang B, Ekdawi SN, Reilly RM, Allen C. Active targeting of block copolymer micelles with trastuzumab fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts. Mol Pharm. 2013;10(11):4229\u201341.","journal-title":"Mol Pharm"},{"key":"2684_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biomaterials.2014.10.069","volume":"39","author":"J Ahn","year":"2015","unstructured":"Ahn J, Miura Y, Yamada N, Chida T, Liu X, Kim A, et al. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials. 2015;39:23\u201330.","journal-title":"Biomaterials."},{"issue":"7","key":"2684_CR13","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1021\/nn4018922","volume":"7","author":"L Fiandra","year":"2013","unstructured":"Fiandra L, Mazzucchelli S, De Palma C, Colombo M, Allevi R, Sommaruga S, et al. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands. ACS Nano. 2013;7(7):6092\u2013102.","journal-title":"ACS Nano"},{"issue":"6","key":"2684_CR14","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1039\/C4NR04426F","volume":"7","author":"A Quarta","year":"2015","unstructured":"Quarta A, Bernareggi D, Benigni F, Luison E, Nano G, Nitti S, et al. Targeting FR-expressing cells in ovarian cancer with fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. Nanoscale. 2015;7(6):2336\u201351.","journal-title":"Nanoscale."},{"issue":"9","key":"2684_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","volume":"119","author":"P Munster","year":"2018","unstructured":"Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody\u2013liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119(9):1086\u201393.","journal-title":"Br J Cancer"},{"issue":"1","key":"2684_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2385-z","volume":"16","author":"K Miller","year":"2016","unstructured":"Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, et al. HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician\u2019s choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer. BMC Cancer. 2016;16(1):1\u201311.","journal-title":"BMC Cancer"},{"key":"2684_CR17","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/IJN.S153795","volume":"13","author":"D Duan","year":"2018","unstructured":"Duan D, Wang A, Ni L, Zhang L, Yan X, Jiang Y, et al. Trastuzumab- and fab\u2019 fragment-modified curcumin PEG -PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine. 2018;13:1831\u201340.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"2684_CR18","first-page":"35","volume":"4","author":"K Subik","year":"2010","unstructured":"Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The expression patterns of ER, PR, HER2, CK5\/6, EGFR, KI-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer Basic Clin Res. 2010;4(1):35\u201341.","journal-title":"Breast Cancer Basic Clin Res"},{"key":"2684_CR19","first-page":"1","volume":"7","author":"I Chung","year":"2016","unstructured":"Chung I, Reichelt M, Shao L, Akita RW, Koeppen H, Rangell L, et al. High cell-surface density of HER2 deforms cell membranes. Nat Commun. 2016;7:1\u201311.","journal-title":"Nat Commun"},{"issue":"9","key":"2684_CR20","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","volume":"103","author":"M Yunokawa","year":"2012","unstructured":"Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012;103(9):1665\u201371.","journal-title":"Cancer Sci"},{"issue":"2","key":"2684_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1021\/bm201479t","volume":"13","author":"B Hoang","year":"2012","unstructured":"Hoang B, Reilly RM, Allen C. Block copolymer micelles target auger Electron radiotherapy to the nucleus of HER2-positive breast cancer cells. Biomacromolecules. 2012;13(2):455\u201365.","journal-title":"Biomacromolecules."},{"issue":"1","key":"2684_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.nucmedbio.2010.06.010","volume":"38","author":"DA Scollard","year":"2011","unstructured":"Scollard DA, Chan C, Holloway CMB, Reilly RM. A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Nucl Med Biol. 2011;38(1):129\u201336.","journal-title":"Nucl Med Biol"},{"key":"2684_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-008-0043-0","volume":"115","author":"J Gao","year":"2009","unstructured":"Gao J, Kou G, Wang H, Chen H, Li B, Dai J, et al. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res Treat. 2009;115:29\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"2684_CR24","volume-title":"Nanomedicines and combination therapy of doxorubicin and Olaparib for treatment of ovarian Cancer","author":"S Eetezadi","year":"2016","unstructured":"Eetezadi S. Nanomedicines and combination therapy of doxorubicin and Olaparib for treatment of ovarian Cancer. 2016."},{"key":"2684_CR25","doi-asserted-by":"crossref","unstructured":"Zhao DZ, Zhao X, Zu Y, Li J, Zhang Y, Jiang R, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010:669\u201377.","DOI":"10.2147\/IJN.S12918"},{"issue":"4","key":"2684_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/adt.2014.573","volume":"12","author":"R Edmondson","year":"2014","unstructured":"Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207\u201318.","journal-title":"Assay Drug Dev Technol"},{"key":"2684_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/onc.2008.394","volume":"28","author":"M Pickl","year":"2009","unstructured":"Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene. 2009;28:461\u201346.","journal-title":"Oncogene."},{"issue":"10","key":"2684_CR28","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1021\/acs.biomac.5b01032","volume":"16","author":"K Wang","year":"2015","unstructured":"Wang K, Kievit FM, Florczyk SJ, Stephen ZR, Zhang M. 3D porous chitosan\u2013alginate scaffolds as an in vitro model for evaluating nanoparticle\u2013mediated tumor targeting and gene delivery to prostate cancer. Biomacromolecules. 2015;16(10):3362\u201372.","journal-title":"Biomacromolecules."},{"issue":"6109","key":"2684_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1126\/science.1226338","volume":"338","author":"Z Cheng","year":"2012","unstructured":"Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338(6109):903\u201310.","journal-title":"Science."},{"issue":"2","key":"2684_CR30","first-page":"265","volume":"2","author":"T Goodman","year":"2007","unstructured":"Goodman T, Olive P, Pun S. Increased nanoparticle penetration in collagenase- treated multicellular spheroids. J Struct Chem. 2007;2(2):265\u201374.","journal-title":"J Struct Chem"},{"key":"2684_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","volume":"66","author":"N Bertrand","year":"2014","unstructured":"Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2\u201325.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"2684_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","volume":"6","author":"H Cabral","year":"2011","unstructured":"Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815\u201323.","journal-title":"Nat Nanotechnol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2684-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-019-2684-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-019-2684-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:13:59Z","timestamp":1611101639000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-019-2684-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2684"],"URL":"https:\/\/doi.org\/10.1007\/s11095-019-2684-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"39"}}